TW201210633A - Agent for promoting hyaluronic acid production - Google Patents
Agent for promoting hyaluronic acid production Download PDFInfo
- Publication number
- TW201210633A TW201210633A TW100128645A TW100128645A TW201210633A TW 201210633 A TW201210633 A TW 201210633A TW 100128645 A TW100128645 A TW 100128645A TW 100128645 A TW100128645 A TW 100128645A TW 201210633 A TW201210633 A TW 201210633A
- Authority
- TW
- Taiwan
- Prior art keywords
- hyaluronic acid
- acid production
- agent
- skin
- present
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 74
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 72
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 22
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 25
- 241000196324 Embryophyta Species 0.000 claims abstract description 21
- 244000017020 Ipomoea batatas Species 0.000 claims description 26
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 9
- 206010003246 arthritis Diseases 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 8
- 238000012423 maintenance Methods 0.000 abstract description 4
- 244000052909 Dioscorea esculenta Species 0.000 abstract description 3
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract description 3
- 230000037394 skin elasticity Effects 0.000 abstract description 2
- 206010042496 Sunburn Diseases 0.000 abstract 1
- 230000037393 skin firmness Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 235000013305 food Nutrition 0.000 description 13
- 239000002537 cosmetic Substances 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 244000077995 Coix lacryma jobi Species 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- JWEHBOYGKRBMBV-UHFFFAOYSA-N 1-ethyl-1-propylhydrazine Chemical compound CCCN(N)CC JWEHBOYGKRBMBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PBKADZMAZVCJMR-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;dihydrate Chemical compound O.O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O PBKADZMAZVCJMR-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CMSYVPIXXGNYEG-RTRLPJTCSA-N N'-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetohydrazide Chemical compound CC(=O)NN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CMSYVPIXXGNYEG-RTRLPJTCSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical group CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- -1 Sucrose ester Chemical class 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940023308 vitamin b6 20 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/064—Proline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21172—Soy Isoflavones, daidzein, genistein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
- A23V2250/284—Oligosaccharides, non digestible
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/314—Ubiquinone, coenzyme Qn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
- A23V2250/51082—Carboxymethyl cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5422—Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6402—Erythritol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
201210633 六、發明說明： 【發明所屬之技術領域】 本發明係有關於具有玻尿酸產生促進作用之玻尿酸產 生促進劑。 【先前技術】 近年來，有關老化的研究日新月異。廣泛地來看，皮 膚老化的原因除了年齢加增之重要因子外，乾燥、氧化、 陽光（紫外線）等影響也是與皮膚老化有關的直接因子。 皮膚老化的具體現象已知為包括玻尿酸為主之醣胺多醣 (glycosaminoglycans)的減少，膠原蛋白交聯反應、紫外 線造成的細胞損傷等。 其中玻尿酸具有細胞間隙水分的保持，基於在組織内 形成果凍狀基質之細胞的保持，組織潤滑性與柔軟性的保 持’對機械傷害等之外力的抵抗，以及防止細菌感染等多 種機能（參照㈣文獻1)。例如，皮膚的玻尿酸量會因 年齢的加增而減少’並伴隨著產生或乾料皮膚老 化。因此，此種老化的皮膚改善劑多數為目前已提出之混 合玻尿酸或膠原蛋白的化粧品。沐 然而，傳統的化粧品只能 發揮皮膚表面的保濕效果，並益沐士断 瘡L t _ 龙無法本質上改善老化的肌 膚。此外，雖然目前有混合各種維 ^ ^ “ 畜4草樂的皮膚細胞 賦活劑，但其仍然無法獲得達到改 文=、治療老化肌膚。 此外，關節液中所含有的玻尿 ^ _會覆盍於關節軟骨的 表面，以有助於關節功能的順利 H乍用。正常人關節液中的 201210633 玻展酸浪度為約2 . 厶3 mg/mi，但在慢性關節炎中，關節液 中的玻尿酸濃度為# i 9 f Λ 又為4 1.2 mg/ml以下，同時關節液的黏度 也有明顯地下降卩i 、 參…非專利文獻2)。此外’化膿性關 節炎或痛風性關節炎等也已知與慢性關節炎相"導致 玻尿酸含量的下降（參照非專利文獻3)。對於上述患者， 為了改善潤滑機能、關節軟骨的被覆.㈣、抑制疼痛以 及病理上關節液的改善或正常化’可考慮增加關節液中玻 尿酸的含量。例如’已有文獻指出對慢性關節炎患者進行 Μ㈣㈣^療法可達到上述的 文獻彳）。同樣地，也有文獻指出外傷性關節炎== 炎或變形性關節炎可利用玻尿酸達到上述的改善效果（參 照非專利文獻5 )。 因此可彳木取在皮膚上塗抹混合玻尿酸的化粧品，或 直接將玻尿m關節中等方法’但由外部給予玻尿酸並 無法獲得根本的改善’無法預期具有足夠的效果。特別是， 具有玻尿酸幾乎不被皮膚所吸收的問題。 因此’期望不僅是由外部補充玻尿酸，而是以人體本 身所具備的自體回復力’利用促進人類皮膚成纖維細胞自 身破尿酸的生成，卩開發可根本改善生物體機能的物質， 在這之中，希1可開發各種植物㈣的玻尿酸產生促進 劑’其具有安全性或對皮膚無刺激性（例 >，參照專利文 獻1〜3 )。 此外，在烫傷後的治療過程中，由壞死組織下方增生 肉芽組織初期至組織全體被肉芽組織置換的期間，肉芽中 4 201210633 的玻尿酸有顯著地增加（非專利文獻6) ’期望玻尿酸產 生促進劑可作為燙傷初期的治療藥物。 【先前技術文獻】 【專利文獻】 【專利文獻1】特開平u_ 209261號公報 【專利文獻2】特開20 07- 84448號公報 【專利文獻3】特開2003 — 55244號公報 【非專利文獻】 【非專利文獻 1 】11 Bio Industry"、vol. 8、p. 346(1991 ) 【非專利文獻 2】"Arthritis Rheumatism"、vol. 10、 p.357(1967) 【非專利文獻3】「結合組成」（金原出版）、481頁、 1 984 年 【非專利文獻4】「炎症」（曰本炎症学会）、11卷、 16 頁、1991 年 【非專利文獻5】「結合組織與疾患」（講談社）、 246 頁、1980 年 【非專利文獻6】「結合組織與疾患」（講談社）、 153 頁、1980 年 【發明内容】 【發明所欲解決之問題】 因此，傳統具有玻尿酸產生促進作用的物質為植物萃 取物，希望可開發各種具有安全性或對皮膚無刺激性的物 201210633 質，需要以至今仍未發現可實現此效果之新植物開發具新 穎之玻尿酸產生促進效果的植物。 為針對上述事情，本發明之目的係為提供新穎之植物 來源的玻尿酸產生促進劑。 【解決問題之技術手段】 本發明人等，有鑑於此，持續深入研究，尋找具有良 好玻尿酸產生促進作用之特定植物或其萃取物，可作為玻 尿酸產生促進劑，以完成本發明。 本發明係提供含有甘薯植物體或其萃取物之玻尿酸產 生促進劑。 在本發明之玻尿酸產生促進劑中，上述植物體可為甘 薯植物體之乾燥粉末。 在本發明之玻尿酸產生促進劑中，上述植物體可為甘 薯植物體之塊莖。 本發明提供包含利用上述玻尿酸產生促進劑的步驟以 防止人類皮膚老化、保持骨架、保持彈力 '及/或改善保濕 性的方法。上述的利用步驟可為經口給予。 【發明的效果】 本發明之玻尿酸產生促進劑具有良好的玻尿酸產生促 進作用，可應用於防止人類皮膚老化、特別是主要為皮膚 骨架或彈力的保持、關節炎的預肖·治療、烫傷的初期治 療。此外，由於使用天然物f來源的成分，屬於即使是人 類或動物服用也為安全的物質。 6 201210633 【實施方式】 【實施發明的形態】 以下詳細說明本發明。 本發明之玻尿酸產生促進劑具有良好的玻尿酸產生促 進能力。因此，本發明之玻尿酸產生促進劑較佳可作為醫 藥品（例如皮膚外用劑、内服藥）、藥粧品、及化粧品的 原料。也可作為食品（例如補給品、飲料）。 本發明中所使用之甘薯（學名：Dioscorea esculenta) 為薯蕷科薯蕷屬的植物。 甘薯主要栽培於九州以南，屬於可食用蕃薯之一種， 具有滋養強壯的功用，含有薯蕷皂素苷或其糖苷（特開2〇〇7 —274985 )。具有抑制 ADAM ( a disintegrin and metall〇protease)的作用，可作為除皺劑使用（特開 94734 )，且薯蕷屬（Di〇sc〇rea)植物可防止皮膚彈性的 喪失及細紋的產生（特表2〇〇4 — 51 5523 )。 然而，無文獻指出甘薯的植物體或其萃取物具有玻尿 酸產生促進作用，此為本發明人首次發現。 本發明中所使用之甘薯可來自各 定，例如，可使用塊莖、根、莖、葉 各種部位’並無特別201210633 VI. Description of the Invention: [Technical Field of the Invention] The present invention relates to a hyaluronic acid production promoter having a hyaluronic acid production promoting action. [Prior Art] In recent years, research on aging has been changing with each passing day. Broadly speaking, in addition to the important factors of ageing, the effects of drying, oxidation, and sunlight (ultraviolet rays) are also direct factors related to skin aging. The specific phenomenon of skin aging is known to include reduction of hyaluronic acid-based glycosaminoglycans, collagen cross-linking reaction, and cell damage caused by ultraviolet rays. Among them, hyaluronic acid has the maintenance of intercellular water, and it is based on the maintenance of cells that form a jelly-like matrix in the tissue, the maintenance of tissue lubricity and flexibility, the resistance to external forces such as mechanical damage, and the prevention of bacterial infections (see (4). Document 1). For example, the amount of hyaluronic acid in the skin is reduced by the increase in annual sputum' accompanied by aging or dry skin aging. Therefore, most of such aged skin improving agents are currently proposed cosmetics which incorporate hyaluronic acid or collagen. However, traditional cosmetics can only exert the moisturizing effect on the surface of the skin, and the Lt _ dragon can not substantially improve the aging skin. In addition, although there are currently a variety of skin cell activators mixed with the animal, it still cannot be obtained to change the text = to treat aging skin. In addition, the hyaluronic acid contained in the joint fluid will be covered. On the surface of articular cartilage, to facilitate the smooth function of joint function. The 201210633 glass development acid wave in normal joint fluid is about 2. 厶3 mg/mi, but in chronic arthritis, in joint fluid The hyaluronic acid concentration is # i 9 f Λ and is 4 1.2 mg/ml or less, and the viscosity of the joint fluid is also significantly decreased. 非i, gin... Non-patent literature 2) In addition, 'septic arthritis or gouty arthritis, etc. It is also known that it causes a decrease in hyaluronic acid content (see Non-Patent Document 3). For the above patients, in order to improve the lubrication function, the attachment of articular cartilage. (4), the inhibition of pain and the improvement or normality of pathological joint fluid "can increase the amount of hyaluronic acid in the joint fluid. For example, 'the literature has pointed out that the treatment of chronic arthritis patients with Μ (4) (4) ^ therapy can achieve the above literature 。). Similarly, there are also literature pointed out Injury arthritis == Inflammation or deformed arthritis can achieve the above-mentioned improvement effect by using hyaluronic acid (refer to Non-Patent Document 5). Therefore, it is possible to apply a hyaluronic acid-mixed cosmetic to the skin, or directly to the hyaluronic m joint. The method 'but the external administration of hyaluronic acid does not give a fundamental improvement' is not expected to have sufficient effect. In particular, it has the problem that hyaluronic acid is hardly absorbed by the skin. Therefore, 'expectation is not only externally supplemented with hyaluronic acid but by the human body itself The self-recovery power is used to promote the formation of uric acid in human skin fibroblasts, and to develop substances that can fundamentally improve the function of living organisms. Among them, Xi 1 can develop a hyaluronic acid production promoter for various plants (4) It is safe or non-irritating to the skin (for example, refer to Patent Documents 1 to 3). In addition, during the treatment after scald, the granulation tissue is replaced by the granulation tissue from the initial stage of the proliferation of granulation tissue under the necrotic tissue. During the period, the hyaluronic acid in the granulation 4 201210633 was significantly increased (Non-Patent Document 6) 'Expected hyaluronic acid The production of the accelerator can be used as a therapeutic drug in the initial stage of the scald. [PRIOR ART DOCUMENT] [Patent Document 1] Japanese Laid-Open Patent Publication No. JP-A No. 209261 (Patent Document 2) JP-A-2006-84448 (Patent Document 3) Japanese Laid-Open Patent Publication No. 2003-55244 [Non-Patent Document] [Non-Patent Document 1] 11 Bio Industry", vol. 8, p. 346 (1991) [Non-Patent Document 2] "Arthritis Rheumatism", vol. 10, p. 357 (1967) [Non-Patent Document 3] "Combination Composition" (Kanahara Publishing), 481 pages, 1 984 [Non-Patent Document 4] "Inflammation" (Sakamoto Inflammation Society), 11 volumes, 16 pages, 1991 [ Non-Patent Document 5] "Combining Organizations and Diseases" (Kodansha), 246 pages, 1980 [Non-Patent Document 6] "Combining Organizations and Diseases" (Kodansha), 153 pages, 1980 [Inventions] [Invented to solve The problem is that the traditional substance that promotes hyaluronic acid production is a plant extract, and it is hoped that various kinds of substances 201210633 which are safe or non-irritating to the skin can be developed. The new plant can achieve this effect with the development of a new plant to produce hyaluronic acid Ying-promoting effect. In order to address the above, an object of the present invention is to provide a novel plant-derived hyaluronic acid production promoter. [Means for Solving the Problems] In view of the above, the inventors of the present invention have conducted intensive studies to find a specific plant or an extract thereof which has a good hyaluronic acid production promoting action, and can be used as a hyaluronic acid production accelerating agent to complete the present invention. The present invention provides a hyaluronic acid production accelerating agent comprising a sweet potato plant body or an extract thereof. In the hyaluronic acid production promoter of the present invention, the plant body may be a dry powder of a sweet potato plant body. In the hyaluronic acid production promoter of the present invention, the plant body may be a tuber of a sweet potato plant body. The present invention provides a method comprising the steps of using the above hyaluronic acid production promoter to prevent aging of human skin, maintaining the skeleton, maintaining elasticity, and/or improving moisture retention. The above utilization steps can be administered orally. [Effects of the Invention] The hyaluronic acid production promoter of the present invention has a good hyaluronic acid production promoting action and can be applied to prevent aging of human skin, in particular, mainly for maintaining the skin skeleton or elasticity, pre-sharp treatment of arthritis, and scald. Initial treatment. Further, since the component derived from the natural substance f is used, it is a substance which is safe even if it is taken by a human or an animal. [Embodiment] [Embodiment of the Invention] Hereinafter, the present invention will be described in detail. The hyaluronic acid production promoter of the present invention has a good hyaluronic acid production promoting ability. Therefore, the hyaluronic acid production accelerating agent of the present invention is preferably used as a raw material for medical drugs (e.g., external preparations for skin, internal medicines), cosmeceuticals, and cosmetics. Can also be used as food (such as supplies, beverages). The sweet potato (scientific name: Dioscorea esculenta) used in the present invention is a plant of the genus Dioscorea. Sweet potato is mainly cultivated in the south of Kyushu. It is a kind of edible sweet potato. It has nourishing and strong function and contains diosgenin or its glycoside (Specially Open 2〇〇7-274985). It has the function of inhibiting ADAM (a disintegrin and metall〇protease) and can be used as a wrinkle remover (Specially Opened 94734), and the Di〇sc〇rea plant can prevent the loss of skin elasticity and the generation of fine lines. Table 2〇〇4 — 51 5523 ). However, there is no literature indicating that the plant body of sweet potato or its extract has a hyaluronic acid production promoting effect, which was first discovered by the inventors. The sweet potato used in the present invention may be derived from various parts, for example, tubers, roots, stems, and leaves may be used.
萃取物、粉碎物、榨汁液、 ，並未特 (列如，可 破碎物、 201210633 化學處理物、酵 本發明中之物’較佳為研磨物、乾燥粉末。 產物，通常莖後所獲得之 本】用各種自動研磨機，或手工作業研磨製備。 中，乾燥粉末可為，例如，來自 用之甘薯的粉碎J如來自本發明中所使 之粉碎物的製=以下稱為本發明之粉碎物）。本發明 使用粉碎機進行Γ，例如可藉由將甘著的塊莖乾燥後， 冷凉粉獲得粉狀的甘著粉碎物。也可藉由 ^ \ SV凍乾燥後進行粉碎以獲得粉碎物。 萃取物為對原料植物使用萃取溶劑經由茬抱半挪 得的物質。萃取汀^ 卒取命劑左由卒取步驟所獲 程H 4藉由—般習知的萃取方法進行下述過 如：將原料粉碎或切碎後，利用溶劑進行一體式 別『或連：式的操作。獲得萃取物時的萃取溶劑並無特 Γ:’可為水、氣仿、乙醇、甲醇、異丙醇等醇類’·丙 基乙基鲷等酮類；醋酸甲酯、醋酸乙醋等親水性或 親油性的溶劍，"5Γ # $ β 了視需要單獨或形成適當混合液使用。在 使用混合液作為萃取溶劑的例子，雖無特別限定，但例如 可使用各種水溶液，例如1〇〜95%，較佳為15〜9⑽更佳 為20 85%之醇類水溶液。可適當地決定萃取溶劑的量， 但通常，對於原料植物，使用時原料植物形態的重量（例 如原料植物若可為生的植物則為生的植物），較佳使用2 〜100倍量的萃取溶劑。萃取溫度較佳根據目的來決定， 但在水萃取時，通常較佳為4〜13〇t，更佳為25〜1〇〇t。 當溶劑中含有乙醇時’由安全性的觀點來看，較佳在4〜 60 C的範圍。萃取時間也可考慮萃取效率來決定但通常 8 201210633 較佳為數秒〜數日，更佳為5分鐘〜24小時的範圍，以設 原料萃取¥劑、萃取溫度。萃取操作，例如可一邊授 拌或靜置一邊進行，若有必要，也可重複數次。 藉由上述步驟，可獲得甘薯萃取物。萃取物可視需要 經由過濾、、離心、濃縮、超過濾、分子篩等處理，以製備 薯蕷皂素苦糖苷濃縮萃取物。此外，也可利用不同萃取方 法由原料植物獲得含有2種以上的萃取物。 本發明之玻尿酸產生促進劑較佳為由甘薯植物體或其 萃取物所衍生之物質，但在不影響本發明效果的範圍下， 也可含有其他各種成分。 本發明之玻尿酸產生促進劑，除了可調配成皮膚外用 劑以使用於人類及動物，除此之外也可調配成各種飲食 、飼料（寵物食品等）來攝取。也可成為醫藥製劑投予 至人類或動物。此時，可根據皮膚外用劑、引食品等劑型· 形態任意地進行乾燥、濃縮或稀釋等調整。 本發明之玻尿酸產生促進劑在調配成皮膚外用劑時， 其混合量（乾燥質量）較佳為外用劑全量中約〇. 〇〇〇1〜U 質量％。 本發明在使用為皮膚外用劑時，除上述成分外，更可 視需要在不影響本發明效果的範圍内，視必要地適當調配 一般用於化粧品或醫藥品等皮膚外用劑的成分，例如抗氧 化劑、油脂、紫外線保護劑、界面活性劑、增稠劑、醇類、 粉末成分、色素、水性成分、水、各種皮膚營養補充劑等。 再者’也可適當調配乙二胺四乙酸二納、L _ 一联四乙 201210633 酸三鈉、檸檬酸鈉、聚磷酸鈉、偏磷酸鈉、葡萄糖酸等的 金屬離子螯合劑；苯甲酸甲酯、苯甲酸乙酯、苯曱酸丁酯 等的防腐劑；咖#因、單寧、維拉帕米（verapami 1)、氨曱 環酸（tranexamicacid)及其衍生物、甘草萃取物、光甘草 定（glabridin)、花梨果實的熱水萃取物、各種生藥、醋 酸鹽維生素E、甘草酸（glycyrrhizinate acid)及其衍生 物或鹽類等的藥劑；維生素C、抗壞血酸磷酸酯鎂、抗壞 血酸葡糖苷、熊果苷、麴酸等的美白劑；葡萄糖、果糖、 甘露糖、蔗糖、海藻糖等的糖類。 此述皮膚外用劑可為用於表皮的化粧品、藥粧品等， 特別適合廣泛使用於化粧品’其劑型只要是可使用於皮膚 劑型皆可，可為溶液系、可溶性系、乳化系、粉末分散系、 ^ /由一層系、水—油—粉末三層系、軟膏、化粧水、凝 膠、氣霧劑等任何劑型。 使用的形態也可為任意，例如可用於化粧水、乳液、 乳霜、面膜等的臉部化粧品或粉底、口紅、眼影等的彩粧 化粧品、芳香化粧品、沐浴劑等。 ，若為彩粧化粧品時，可廣泛地為粉底等、盥洗製品之 心、肥皂等的形態。而且’若為藥粧品，可廣泛地為各 :軟膏劑等的形態。因&，本發明之玻尿酸產生促進劑並 特別限定使用上述劑型及形態。 本發明之玻尿酸產生促進劑在調配於飲食品或飼料 定植：根據其種類…、形態、利用方法等，適當地決 體或其萃取物的混合量（乾燥質量），例如，在飲 10 201210633 食品的總量中’錠劑或 0/甘叢專的情形時較佳為1〜90質量 0其匕飲食品為0.001〜@·θ〇/ , ^ 〇質置％。成人每曰的植物啖其 卒取物的攝取量較佳調製 物次其 作為保健用飲食品時，較佳 I 心特別是’在 定效果的量。 Me可發揮本發明有效成分特 作為飲食品或飼料的形能，k m t ㈣’例如可任意形成顆粒狀、 粒狀、膏狀、凝膠狀、固體壯、 * u遐狀、或液體狀。在這些中，可 適當地含有被認同含於飲食品錄 T tfj A知各種物質，例如社 合劑、崩散劑、增黏劑、分散劑、 '° … 4 丹及收促進劑、調味劑、 緩衝劑、界面活性劑、增溶密丨 J ^合劑、保存劑、乳化劑'等滲透 劑、安定劑或pH值調控劑等的賦形剤。 / 本發明之玻尿酸產生促進劑在❹為醫藥製劑時，此 製劑可為經口或非經口（靜脈投予、腹腔内投予等）適宜 使用。劑型可任意地以公知方法適宜製備為例如旋劑、顆 粒劑、散劑、膠囊等的經口的固形製劑；#内服液劑、糖 漿等的經口的液體製劑；或注射劑等非經口液體製劑等。 在這些醫藥品中，可適當地使用一般使用的結合劑、崩散 劑、增黏劑、分散劑、再吸收促進劑、調味劑、緩衝劑、 界面活性劑、增溶劑、保存劑、乳化劑、等滲透劑、安定 劑或pH值調控劑等賦形剤。 本發明之玻尿酸產生促進劑在作為皮膚外用劑、飲食 品、醫藥製劑等使用時’藉由良好的玻尿酸產生促進作用， 有效地用於防止人類皮膚老化、保持皮膚張力或彈力、關 節炎等的預防•治療、燒烫傷的初期治療等。在添加至食 11 201210633 品中時，藉由直接攝取食品 生促進效果。 可預期由其中發揮玻尿酸產 以上述症狀或病態等的治療、預防、改善等生理機能 之概& τ應用於顯示其目的的皮膚外用劑、機能性飲食 品、特定保健用食品等。 而且本發明玻尿酸產生促進劑在添加至皮膚外用劑 或飲等方法’可預先添加，也可在製造過程中添加， 可考慮作業性而適當地選擇。 【實施例】 本發明列舉下述之實施例更進一步詳述，但本發明部 限定於此。混合量無特別註明者，以質量％表示。 本實施例中，甘薯使用「甘薯粉末」（Takara Βι〇公 司製）之DMSO ( Dimethyl sulfoxide)溶解物。首先，說 明關於玻尿酸產生促進效果試驗方法的結果。 1·玻尿酸產生促進效果試驗方法 將上述所得之試料進行玻尿酸產生促進作用的評估。 也就是說，在24孔盤中接種5. Οχΐ 〇4細胞/孔濃度的人類 表皮角質細胞’在細胞佔滿生長平面空間時，添加含有各 種試料的500 # L EpiLife-KG2培養液（最終濃度j 以g/mL、10 // g/mL)。添加後，經72小時的培養，利用 ELISA法測定玻尿酸產量。使用])MS0/PBS溶液（無添加試 料）作為對照組（control )。 使用玻尿酸分析套組（Hyaluronan assay kit)(生 物化學生物技術公司製）進行偵測。偵測值的單位以破尿 12 201210633 酸（hyaluronan。與玻尿酸同義）的產量（ng/mL)表示。 2.結果 與對照組相比，以含有甘薯之培養基培養的細胞的玻 尿酸量大幅地增加。也就是說，可確認甘薯具有極佳的玻 尿酸產生促進效果。其結果如第1圖所示。 由第1圖可知，本發明之植物具有良好的玻尿酸產生 促進效果，有效為玻尿酸產生促進劑。 因此’可藉由調配本發明之玻尿酸產生促進劑，提供 具有玻尿酸產生促進效果的皮膚外用劑、經口組成物（例 如機能劑、飲食品等）、醫藥製劑，以達成各種症狀或疾 病、病態等的預防、防止、改善、治療等。 具體的適用例可擇自預防 '改善、治療皮膚鬆弛•皺 紋、彈性•彈力低下等的皮膚老化；關節炎的預防•治療； 燒烫傷初期的治療。但不限於此所述例示之適用。 以下對各種劑型之本發明玻尿酸產生促進劑之調配例 的配方例進行說明。本發明不限於此述配方例，也不限於 專利所請求的範圍。在下述配方例中，使用Takara Bio公 司製的「甘薯粉末」作為玻尿酸產生促進劑。 〔調配配方例1 :糖果〕 砂糖 180G mg 糖漿 1 926 mg 玻尿酸産生促進劑： 甘薯粉末（乾燥質量） 200 mg 膠原蛋白胜肽 30 mg 13 201210633 薏仁萃取物（乾燥質量） 2 mg 蓮花胚芽萃出物（乾燥質量） 2 mg 香料 40 mg (合計） 4000 mg 〔調配配方例2 :錠劑〕 蔗糖酯 70 mg 結晶纖維素 74 mg 曱基纖維素 36 mg 甘油 25 mg 玻尿酸產生促進劑： 甘薯粉末（乾燥質量） 120 mg 膠原蛋白胜肽 60 mg 薏仁萃取物（乾燥質量） 10 mg N _乙醯葡糖胺 180 mg 玻尿酸 150 mg 維生素E 30 mg 維生素B6 20 mg 維生素B2 10 mg α —硫辛酸 20 mg 輔酶Q10 40 mg 神經醯胺（筠翁萃取物） 55 mg L _脯胺酸 300 mg (合計） 1200 mg 14 201210633 〔調配配方例3 :軟膠囊〕 食用大豆油 528 mg 玻尿酸産生促進劑： 甘薯粉末（乾燥質量） 90 mg 膠原蛋白胜肽 45 mg 薏仁萃取物（乾燥質量） 8 mg 蓮花胚芽萃取物（乾燥質量） 16 mg 蜂王漿 70 mg 馬卡（Maca) 60 mg GABA ( = r—胺基丁酸） 30 mg 蜂蠟 60 mg 明膠 375 mg 甘油 113 mg 脂肪酸甘油酯 105 rag (合計） 1500 mg 〔調配配方例4 :軟膠囊〕 糙米胚芽油 650 mg 玻尿酸產生促進劑： 甘薯粉末（乾燥質量） 300 mg 膠原蛋白胜肽 255 mg 薏仁萃取物（乾燥質量） 50 mg 白藜蘆醇 5 mg 彈力蛋白（elastin) 180 mg 15 201210633 DNA 30 mg 葉酸 30 mg (合計） 1500 mg 〔調配配方例5 :顆粒〕 玻尿酸産生促進劑： 甘薯粉末（乾燥質量） 140 mg 膠原蛋白胜肽 70 mg 薏仁萃取物（乾燥質量） 20 mg 蓮花胚芽萃取物（乾燥質量） 40 mg 維生素C 150 mg 大豆異黃酮 270 mg 還原乳糖 360 mg 大豆寡醣 36 mg 赤蘚糖醇 36 mg 糊精 30 mg 香料 24 mg 檸檬酸 24 mg (合計） 1200 mg 〔調配配方例6 :保健飲料 (50 mL 中）〕 玻尿酸産生促進劑： 甘薯粉末（乾燥質量） 100 mg 膠原蛋白胜肽 5 mg 薏仁萃取物（乾燥質量） 2 mg 16 201210633 還原麥芽糖漿 28 mg 赤蘚糖醇 8 mg 擰檬酸 2 rag 香料 1. 3 mg N —乙醯葡萄糖胺 1 mg 玻尿酸 0.5 mg 維生素E 0. 3 mg α —硫辛酸（α-lipoic acid) 0. 2 mg 輔酶Q10 1. 2 mg 神經醯胺（筠篛萃取物） 0. 4 mg L —脯胺酸 2 mg 水 剩餘 【圖式簡單說明】 第1圖顯示甘薯之玻尿酸產生促進效果試驗的結果。 【主要元件符號說明】 無 17The extract, the pulverized material, the squeezing sap, and the sap, are not particularly useful (for example, the smashable material, the 201210633 chemical treatment, the yeast invention) is preferably an abrasive, a dry powder. The product is usually obtained after the stem. The present invention can be prepared by using various automatic grinders or by manual work. The dry powder can be, for example, the pulverization J from the sweet potato used, such as the pulverized material obtained from the present invention = hereinafter referred to as the pulverization of the present invention. ()). In the present invention, the crucible is used for the crucible, and for example, the dried briquettes can be dried to obtain a powdery gummy pulverized material. It can also be pulverized by freeze drying after ^ \ SV to obtain a pulverized product. The extract is a substance which is half-obtained by using an extraction solvent to the raw material plant. Extracting Ting ^ Stroke Remnant Left from the stroke step H 4 by the conventional extraction method to do the following: After crushing or chopping the raw materials, use the solvent for the integrated type or even: Operation. The extraction solvent for obtaining the extract has no special features: 'may be alcohol, such as water, gas, ethanol, methanol, isopropanol, etc., ketones such as propylethyl hydrazine; hydrophilic groups such as methyl acetate and ethyl acetate Sexual or lipophilic dissolution of the sword, "5Γ # $ β is used as needed or formed as a suitable mixture. The example in which the mixed solution is used as the extraction solvent is not particularly limited, and for example, various aqueous solutions can be used, for example, from 1 to 95%, preferably from 15 to 9 (10), more preferably from 20 to 85%, of an aqueous alcohol solution. The amount of the extraction solvent can be appropriately determined. However, in general, for the raw material plant, the weight of the raw plant form when used (for example, a plant in which the raw plant can be a living plant) is preferably used in an amount of 2 to 100 times. Solvent. The extraction temperature is preferably determined depending on the purpose, but in the case of water extraction, it is usually preferably 4 to 13 Torr, more preferably 25 to 1 Torr. When the solvent contains ethanol, it is preferably in the range of 4 to 60 C from the viewpoint of safety. The extraction time can also be determined in consideration of the extraction efficiency, but usually 8 201210633 is preferably in the range of several seconds to several days, more preferably in the range of 5 minutes to 24 hours, and the raw material is extracted and the extraction temperature is set. The extraction operation can be carried out, for example, while stirring or standing, and if necessary, it can be repeated several times. By the above steps, a sweet potato extract can be obtained. The extract may be treated by filtration, centrifugation, concentration, ultrafiltration, molecular sieve or the like as needed to prepare a concentrated extract of diosgenin. Further, it is also possible to obtain two or more kinds of extracts from the raw material plants by different extraction methods. The hyaluronic acid production accelerating agent of the present invention is preferably a substance derived from a sweet potato plant body or an extract thereof, but may contain other various components insofar as the effects of the present invention are not impaired. The hyaluronic acid production-promoting agent of the present invention can be used for humans and animals in addition to being formulated as a skin external preparation, and can be ingested into various foods and feeds (pet foods, etc.). It can also be administered as a pharmaceutical preparation to humans or animals. In this case, it can be arbitrarily adjusted by drying, concentration, or dilution according to the dosage form and form of the external preparation for skin and the food. When the hyaluronic acid production promoter of the present invention is formulated into a skin external preparation, the amount of the preparation (dry mass) is preferably about 〜1 to U% by mass of the total amount of the external preparation. When the present invention is used as a skin external preparation, in addition to the above-mentioned components, it is also possible to appropriately mix ingredients generally used for external preparations for skin such as cosmetics or pharmaceuticals, such as antioxidants, as long as the effects of the present invention are not impaired. , oils and fats, UV protectants, surfactants, thickeners, alcohols, powder components, pigments, water-based ingredients, water, various skin nutrient supplements, etc. Furthermore, it is also possible to appropriately mix a metal ion chelating agent such as ethylenediaminetetraacetate dihydrate, L _ yilian tetraethyl 201210633 acid trisodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, etc.; Preservatives such as ester, ethyl benzoate, butyl benzoate; coffee#, tannin, verapami 1, tranexamic acid and its derivatives, licorice extract, light Glacidin, hot water extract of rosehip fruit, various crude drugs, acetate vitamin E, glycyrrhizinate acid and its derivatives or salts; vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside A whitening agent such as arbutin or citric acid; a saccharide such as glucose, fructose, mannose, sucrose or trehalose. The external preparation for skin may be a cosmetic or a cosmeceutical for epidermis, and is particularly suitable for use in cosmetics. The dosage form may be used in a skin form, and may be a solution system, a soluble system, an emulsion system, or a powder dispersion system. , ^ / by a layer, water-oil-powder three-layer system, ointment, lotion, gel, aerosol and other dosage forms. The form to be used may be any, for example, a face cosmetic such as a lotion, an emulsion, a cream, a mask, or the like, a make-up of a foundation, a lipstick, an eye shadow, or the like, a cosmetic, a bathing agent, and the like. In the case of a makeup cosmetic, it can be widely used as a foundation, a heart of a washing product, a soap or the like. Further, if it is a cosmeceutical product, it can be widely used in the form of an ointment or the like. The hyaluronic acid production promoter of the present invention is specifically limited to the above-mentioned dosage form and form. The hyaluronic acid production accelerating agent of the present invention is formulated in a food or beverage or a foodstuff: according to the type, form, utilization method, etc., the amount of the compound or the amount of the extract (dry mass) is appropriately, for example, at 10 201210633 In the case of the total amount of the tablet or the 0/Gan Cong, it is preferably 1 to 90 masses, and the food and drink is 0.001 to @·θ〇/, and the content of the enamel is set to %. In the adult, the amount of the plant to be harvested is preferably adjusted. When it is used as a food or drink for health care, it is preferable that the heart is particularly effective. Me can exert the shape of the active ingredient of the present invention as a food or drink or a feed, and k m t (tetra) can be arbitrarily formed into a granular form, a granular form, a paste form, a gel form, a solid form, a * u shape, or a liquid form. Among these, various substances which are recognized to be included in the food and beverage record T tfj A, such as a social agent, a disintegrating agent, a viscosity increasing agent, a dispersing agent, a '4 ... Dan and a promoter, a flavoring agent, a buffering agent, may be appropriately contained. Forming agents such as a penetrating agent such as a surfactant, a surfactant, a solubilizing agent, a preservative, an emulsifier, a stabilizer, or a pH adjuster. / The hyaluronic acid production promoting agent of the present invention may be suitably used orally or parenterally (intravenous administration, intraperitoneal administration, etc.) when it is a pharmaceutical preparation. The dosage form can be arbitrarily prepared by a known method into an oral solid preparation such as a granule, a granule, a powder, a capsule, or the like; an oral liquid preparation such as an internal liquid preparation, a syrup, or the like; or a non-oral liquid preparation such as an injection. Wait. Among these pharmaceuticals, generally used binders, disintegrators, tackifiers, dispersants, resorption enhancers, flavoring agents, buffers, surfactants, solubilizers, preservatives, emulsifiers, and the like can be suitably used. An osmotic agent, a stabilizer, or a pH regulator. When used as an external preparation for skin, a food or drink, a pharmaceutical preparation, etc., the hyaluronic acid production-promoting agent of the present invention is effective for preventing skin aging, maintaining skin tension or elasticity, arthritis, etc. by promoting the promotion of hyaluronic acid. Prevention, treatment, initial treatment of burns, etc. When added to Foods 11 201210633, the effect is promoted by direct ingestion of food. It is expected that the physiological functions such as treatment, prevention, and improvement such as the above-mentioned symptoms and pathologies of hyaluronic acid can be applied to skin external preparations, functional foods, and specific health foods for displaying the purpose. Further, the hyaluronic acid production promoter of the present invention may be added in advance in a method of adding to a skin external preparation or a drink, or may be added during the production process, and may be appropriately selected in consideration of workability. [Examples] The present invention will be described in further detail with reference to the following examples, but the invention is limited thereto. The amount of mixing is not specified, and is expressed in mass%. In the present embodiment, DMSO (Dimethyl sulfoxide) solute of "sweet potato powder" (Takara Βι〇 Co., Ltd.) was used for the sweet potato. First, the results of the test method for the hyaluronic acid production promoting effect will be described. 1. Test method for promoting hyaluronic acid production The sample obtained above was evaluated for the hyaluronic acid production promoting action. That is, in a 24-well plate, 5 Οχΐ 细胞 4 cells/well concentration of human epidermal keratinocytes' was added to the 500 # L EpiLife-KG2 medium containing various samples when the cells occupied the growth plane space (final concentration) j is g/mL, 10 // g/mL). After the addition, the hyaluronic acid production was measured by ELISA for 72 hours. The]MS0/PBS solution (without added sample) was used as a control (control). Detection was carried out using a Hyaluronan assay kit (manufactured by Biochemical Biotechnology Co., Ltd.). The unit of detection value is expressed as the production (ng/mL) of the acid 2012 (hyaluronan. synonymous with hyaluronic acid). 2. Results The amount of hyaluronic acid in cells cultured in a medium containing sweet potato was significantly increased as compared with the control group. In other words, it can be confirmed that sweet potato has an excellent hyaluronic acid production promoting effect. The result is shown in Fig. 1. As is apparent from Fig. 1, the plant of the present invention has a good hyaluronic acid production promoting effect and is effective as a hyaluronic acid production accelerating agent. Therefore, by adding the hyaluronic acid production promoter of the present invention, an external preparation for skin having a hyaluronic acid production-promoting effect, an oral composition (for example, a functional preparation, a food or drink, etc.), and a pharmaceutical preparation can be provided to achieve various symptoms or diseases and pathologies. Prevention, prevention, improvement, treatment, etc. Specific application examples can be selected to prevent 'improvement, treatment of skin sagging, wrinkles, elasticity, low elasticity and other skin aging; prevention and treatment of arthritis; early treatment of burns. However, it is not limited to the application of the illustrated examples. Hereinafter, a formulation example of a formulation example of the hyaluronic acid production promoter of the present invention in various dosage forms will be described. The present invention is not limited to the formulation examples described above, nor is it limited to the scope of the patent. In the following formulation examples, "sweet potato powder" manufactured by Takara Bio Co., Ltd. was used as a hyaluronic acid production promoter. [Formulation Formula 1 : Confectionery] Sugar 180G mg Syrup 1 926 mg Hyaluronic Acid Production Accelerator: Sweet Potato Powder (Dry Quality) 200 mg Collagen Peptide 30 mg 13 201210633 Coix Seed Extract (Dry Quality) 2 mg Lotus Germ Extract (dry mass) 2 mg Flavor 40 mg (total) 4000 mg [Formulation Formula 2: Lozenges] Sucrose ester 70 mg Crystalline cellulose 74 mg Mercapto cellulose 36 mg Glycerol 25 mg Hyaluronic acid production promoter: Sweet potato powder (dry Quality) 120 mg Collagen peptide 60 mg Coix seed extract (dry mass) 10 mg N _ acetoglucosamine 180 mg Hyaluronic acid 150 mg Vitamin E 30 mg Vitamin B6 20 mg Vitamin B2 10 mg α-lipoic acid 20 mg Coenzyme Q10 40 mg ceramide (grass extract) 55 mg L _proline 300 mg (total) 1200 mg 14 201210633 [Formulation Formula 3: Soft Capsule] Edible Soybean Oil 528 mg Hyaluronic Acid Production Accelerator: Sweet Potato Powder ( Dry Quality) 90 mg Collagen Peptide 45 mg Coix Seed Extract (Dry Quality) 8 mg Lotus Germ Extract (Dry Quality) 16 mg Royal Jelly 70 mg Maca 60 mg GABA ( = r-aminobutyric acid) 30 mg Beeswax 60 mg Gelatin 375 mg Glycerin 113 mg Fatty acid glyceride 105 rag (total) 1500 mg [Formulation Formula 4: Soft Capsule] Brown rice germ oil 650 mg Hyaluronic acid production promoter: Sweet potato powder (dry quality) 300 mg Collagen peptide 255 mg Coix seed extract (dry mass) 50 mg Resveratrol 5 mg Elastin 180 mg 15 201210633 DNA 30 mg Folic acid 30 mg (total) 1500 mg [Formulation Formula 5: Granules] Hyaluronic acid production promoter: Sweet potato powder (dry quality) 140 mg Collagen peptide 70 mg Coix seed extract (dry quality) 20 mg Lotus germ extraction (dry mass) 40 mg Vitamin C 150 mg Soy isoflavones 270 mg Reduced lactose 360 mg Soy oligosaccharides 36 mg Erythritol 36 mg Dextrin 30 mg Perfume 24 mg Citric acid 24 mg (total) 1200 mg [Formulation formula Example 6: Health Drink (in 50 mL)] Hyaluronic Acid Production Accelerator: Sweet Potato Powder (Dry Quality) 10 0 mg Collagen peptide 5 mg Coix seed extract (dry mass) 2 mg 16 201210633 Reducing maltose syrup 28 mg Erythritol 8 mg citric acid 2 rag Flavor 1. 3 mg N - acetaminoglucosamine 1 mg hyaluronic acid 0.5 Mg vitamin E 0. 3 mg α-lipoic acid 0. 2 mg Coenzyme Q10 1. 2 mg ceramide (筠篛 extract) 0. 4 mg L — valine 2 mg water remaining [ Brief Description of the Drawings Fig. 1 shows the results of the test for promoting the hyaluronic acid production of sweet potato. [Main component symbol description] None 17
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010204407A JP2012056919A (en) | 2010-09-13 | 2010-09-13 | Hyaluronic acid production promotor |
| PCT/JP2011/067829 WO2012035904A1 (en) | 2010-09-13 | 2011-08-04 | Agent for promoting hyaluronic acid production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201210633A true TW201210633A (en) | 2012-03-16 |
Family
ID=45831378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100128645A TW201210633A (en) | 2010-09-13 | 2011-08-11 | Agent for promoting hyaluronic acid production |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2012056919A (en) |
| TW (1) | TW201210633A (en) |
| WO (1) | WO2012035904A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2527344C2 (en) * | 2012-09-03 | 2014-08-27 | Закрытое акционерное общество "Эвалар" | Composition for internal use for hormone skin aging correction |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101840508B1 (en) * | 2011-04-28 | 2018-03-20 | 비에이취엔 가부시끼가이샤 | Beautiful-skin-promoting agent and use thereof |
| WO2014041528A2 (en) * | 2012-09-14 | 2014-03-20 | Martin Roslain Margaret | A composition |
| PH12013000060A1 (en) | 2013-02-15 | 2016-10-17 | Leano Milagros | Pharmacological indications and uses of preparations from dioscorea hispida |
| CN108135201A (en) * | 2015-07-09 | 2018-06-08 | G·诺法 | Espresso type (ESPRESSO) beverage preparation object comprising collagen peptide |
| JP6330119B2 (en) * | 2016-04-27 | 2018-05-30 | 株式会社東洋新薬 | Beauty composition |
| JP6218915B1 (en) * | 2016-12-26 | 2017-10-25 | 株式会社東洋新薬 | Beauty composition |
| CN114404533B (en) * | 2022-03-31 | 2022-07-08 | 江西纤仁本草堂生物科技有限公司 | Medicine for treating burn and scald and its preparing process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003312344A (en) * | 2002-04-24 | 2003-11-06 | Nissan Motor Co Ltd | Seat belt guide structure |
| JP2007274985A (en) * | 2006-04-07 | 2007-10-25 | Takara Bio Inc | Food containing treated product derived from dioscorea esculenta |
| JP2008094734A (en) * | 2006-10-10 | 2008-04-24 | Shiseido Co Ltd | Antiwrinkle agent and external preparation for skin |
-
2010
- 2010-09-13 JP JP2010204407A patent/JP2012056919A/en active Pending
-
2011
- 2011-08-04 WO PCT/JP2011/067829 patent/WO2012035904A1/en active Application Filing
- 2011-08-11 TW TW100128645A patent/TW201210633A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2527344C2 (en) * | 2012-09-03 | 2014-08-27 | Закрытое акционерное общество "Эвалар" | Composition for internal use for hormone skin aging correction |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012056919A (en) | 2012-03-22 |
| WO2012035904A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2459161B1 (en) | Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra sphenanthera | |
| EP2506723B1 (en) | Acacia macrostachya seed extract and compositions containing same | |
| TW201210633A (en) | Agent for promoting hyaluronic acid production | |
| JP6670166B2 (en) | Cosmetics | |
| CA2821876A1 (en) | Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same | |
| CN113694115A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| CN108697685A (en) | Containing moracin, Phellinus copper G or the root bark of white mulberry, the prevention of muscle disease and treatment is used or muscular function improvement composition | |
| JP2009046465A (en) | Skin cosmetic and food/drink | |
| JP2002293736A (en) | Maillard reaction inhibitor and composition containing the same | |
| JP2010095529A (en) | Composition for improving lipid metabolism | |
| WO2008029877A1 (en) | Anti-aging agent, skin-whitening agent, anti-oxidative agent, and anti-inflammatory agent | |
| JP2009107965A (en) | Ceramide synthesis promoter, and external preparation for skin and food and drink | |
| JP6055667B2 (en) | Collagen production promoter | |
| JP2006311804A (en) | Skin-whitening composition formulated with zinc gluconate | |
| JP2023118853A (en) | Anti-aging composition, anti-aging skin cosmetics and anti-aging food and drink | |
| JP2011042627A (en) | Hyaluronic acid synthesis promoter | |
| JP5534654B2 (en) | Anti-inflammatory agent | |
| JP5220346B2 (en) | Skin cosmetics | |
| JP4722595B2 (en) | Anti-inflammatory agents, antioxidants and whitening agents, and skin cosmetics | |
| KR20200081599A (en) | Cosmetic composition comprising seaweed fermented extract | |
| CN104173392A (en) | Natural product inhibitors of 3dg | |
| JP2005220100A (en) | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink | |
| KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
| JP2021143131A (en) | Anti-aging agent, skin cosmetic and oral composition | |
| JP5422137B2 (en) | Whitening agent, tyrosinase activity inhibitor, melanin production inhibitor, and skin external preparation for whitening |